Branelie Health Inc. seeks patent protection for a computer-implemented method and system for predicting appropriateness of treatment options for the management of traumatic brain injuries, particularly concussions.
Neuroone Medical Technologies Corp. received U.S. FDA 510(k) clearance for its Onerf ablation system which is capable of both recording electrical activity and ablation of nervous tissue.
Sound Wave Innovation Co. Ltd. seeks patent protection for a method of using an ultrasonic device which transmits non-converging ultrasonic energy to the brain for the treatment of dementia, including mild Alzheimer’s-type dementia and mild cognitive impairment.
Carthera SA received an additional €4.5 million (US$4.9 million) from investors to take its series B funding round to €42 million despite a tough fundraising environment for med-tech companies. Frédéric Sottilini, CEO of Carthera, told BioWorld that the strong investor interest was testament to their confidence in the company’s Sonocloud technology for brain disorder treatment.
With an urgent need to create new technologies to improve the detection of traumatic brain injuries (TBI), researchers from the University of Birmingham, U.K., have designed and developed a diagnostic device that can detect TBI by shining a laser into the eye.
Integra Lifesciences Holdings Corp. agreed to acquire Acclarent Inc. from Johnson & Johnson’s Ethicon Inc. subsidiary for $275 million in cash at closing with a further $5 million contingent on achievement of certain regulatory milestones.
Patent applications from Bellevue, Wash.-based Aiberry Inc. describe further aspects of its artificial intelligence (AI)-powered mental health screening platform that is designed to improve efficiency and save time for healthcare providers.
Neuronetics Inc. gained expanded approval in Japan for its transcranial magnetic stimulation (TMS) system to treat major depressive disorder called the Neurostar TMS, helping the Malvern, Pa.-based company increase its footprint in Asia.
Spark Biomedical Inc. is seeking patent protection for the use of its transcutaneous auricular neurostimulation (tAN) platform for treating stress and improving performance in stressful situations while controlling bleeding.
Rewalk Robotics Ltd. has integrated advanced sensing technologies and artificial intelligence (AI) into its latest exoskeleton prototype to enable autonomous decisionmaking. This milestone, coupled with Rewalk’s capabilities, holds enormous potential to create a new generation of exoskeletons that are more intuitive and respond to real-world conditions that users encounter daily, Rewalk CEO Larry Jasinski told BioWorld.
RSS
